[1]张灵云① 宋志强*** 周丽雅** 张建中② 丁钰.基于胃镜的个体化诊断在幽门螺杆菌根除中 应用研究[J].中国微创外科杂志,2015,15(6):497-501.
　Zhang Lingyun,Song Zhiqiang*,Zhou Liya*,et al.Application of Endoscopy-based Tailored Therapy in the Eradication of Helicobacter pylori[J].Chinese Journal of Minimally Invasive Surgery,2015,15(6):497-501.
点击复制

基于胃镜的个体化诊断在幽门螺杆菌根除中 应用研究()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
15
期数:
2015年6期
页码:
497-501
栏目:
临床论著
出版日期:
2015-06-20

文章信息/Info

Title:
Application of Endoscopy-based Tailored Therapy in the Eradication of Helicobacter pylori
作者:
张灵云① 宋志强*** 周丽雅** 张建中② 丁钰
北京大学第三医院消化科，北京100191
Author(s):
Zhang Lingyun;  Song Zhiqiang*;  Zhou Liya*;  et al.
*Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
关键词:
幽门螺杆菌; 根除率; 个体化方案; 抗生素耐药; 胃镜
Keywords:
Helicobacter pylori; Eradication; Tailored therapy; Antibiotic resistance; Gastroscopy
分类号:
R573
文献标志码:
A
摘要:
目的探讨基于胃镜的个体化根除治疗在幽门螺杆菌感染初治和复治患者中的疗效、安全性和依从性。方法2013年3月~2014年6月于我院行胃镜检查并明确幽门螺杆菌感染的患者，胃镜下取胃黏膜标本进行幽门螺杆菌菌株培养、药物敏感性试验和细胞色素P450同工酶2C19基因型检测。根据克拉霉素是否敏感选用克拉霉素或替硝唑，基因型为快、慢及中间代谢型分别选用雷贝拉唑或埃索美拉唑，联合阿莫西林组成三联方案，疗程10天，治疗结束后4～12周复查尿素呼气试验，确定幽门螺杆菌感染是否被成功根除。 结果共318例初治和62例复治患者幽门螺杆菌培养成功，接受个体化治疗，培养成功率分别为90.9%（318/350）和91.2%（62/68），纳入意向性分析；最终298例初治和59例复治患者完成治疗和随访，纳入遵循方案分析。幽门螺杆菌感染初治及复治患者的根除率，意向性分析分别为88.7%（95%可信区间为85.2%～92.1%）和75.8%（65.1%～86.5%），遵循方案分析分别为93.3%（89.9%～96.0%）和79.7%（69.7%～89.7%）。2组不良反应发生率分别为22.0%（70/318）和33.9%（21/62），依从性分别为94.3%（300/318）和95.2%（59/62）。结论基于胃镜的个体化治疗在幽门螺杆菌感染初治患者中根除率较为理想，而在复治患者中疗效欠佳。
Abstract:
ObjectiveTo determine the eradication efficacy, safety, and compliance of endoscopy-based tailored therapy in the initial and retreated patients with Helicobacter pylori infection. MethodsBetween May 2013 and June 2014, patients with dyspepsia (18-70 years old) diagnosed as having infection of Helicobacter pylori under gastroscopy in our hospital were recruited into the study. Gastric mucosa specimens taken with the gastroscopy were cultured for Helicobacter pylori and then antibiotics sensitivity and cytochrome P450 isoenzyme 2C19 genotype were detected. Medications for tailored therapy included amoxicillin and were adjusted based on clarithromycin sensitivity (clarithromycin or tinidazole) and cytochrome P450 isoenzyme 2C19 genotype (rabeprazole or esomeprazole). Eradication status was assessed 4-12 weeks after treatment with urea breath test. ResultsA total of 318 initially-treated and 62 retreated cases of infection of Helicobacter pylori had successful culture of Helicobacter pylori and the culture success rates were 90.9% (318/350) and 91.2% (62/68), respectively. These cases were included in the intention-to-treat analyses. Finally 298 initially-treated and 59 retreated cases completed the treatment and follow-up and were included in the per-protocol analyses. The eradication rates of endoscopy-based tailored therapy in the initially-treated and the retreated cases were 88.7% (95% confidence interval, 85.2%-92.1%) and 75.8% (95% confidence interval,65.1%-86.5%) in intention-to-treat analyses, and 93.3% (95% confidence interval,89.9%-96.0%) and 79.7% (95% confidence interval,69.7%-89.7%) in per-protocol analyses. The rates of adverse effects were 22.0% (70/318) and 33.9% (21/62) in the two groups. The compliance of the two groups was 94.3% (300/318) and 95.2% (59/62), respectively. ConclusionEndoscopy-based tailored therapy has a satisfactory eradication efficacy in initially-treated patients with Helicobacter pylori infection, but a poor eradication efficacy in retreated patients.

参考文献/References:

[1]Song Z,Zhang J,He L,et al.Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients.Dig Liver Dis,2014,46(12):1077-1081.
[2]Graham DY,Fischbach L.Helicobacter pylori treatment in the era of increasing antibiotic resistance.Gut,2010,59(8):1143-1153.
[3]Malfertheiner P,Megraud F,O’Morain CA,et al.Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report.Gut,2012,61(5):646-664.
[4]中华医学会消化病学分会幽门螺杆菌学组,全国幽门螺杆菌研究协作组.第四次全国幽门螺杆菌感染处理共识报告.中华内科杂志,2012,51(10):832-837.
[5]Liu G,Xu X,He L,et al. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children.Helicobacter, 2011, 16(5):356-362.
[6]Yamada S,Onda M,Kato S,et al.Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations.J Gastroenterol,2001,36(10):669-672.
[7]Treiber G,Wittig J,Ammon S,et al.Clinical outcome and influencing factors of a new shortterm quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).Arch Intern Med,2002,162(2):153-160.
[8]Lesaffre E,de Klerk E.Estimating the power of complianceimproving methods.Control Clin Trials,2000,21(6):540-551.
[9]Rimbara E,Fischbach LA,Graham DY.Optimal therapy for Helicobacter pylori infections.Nat Rev Gastroenterol Hepatol,2011,8(2):79-88.
[10]Zhou L,Zhang J,Chen M,et al.A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection:a randomized multicenter trial.Am J Gastroenterol,2014,109(4):535-541.
[11]egraud F.The challenge of Helicobacter pylori resistance to antibiotics:the comeback of bismuth-based quadruple therapy.Therap Adv Gastroenterol,2012,5(2):103-109.
[12]Fischbach L,Evans EL.Meta-analysis:the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.Aliment Pharmacol Ther,2007,26(3):343-357.
[13]Furuta T,Sugimoto M,Yamade M,et al.Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.J Clin Pharmacol,2014,54(3):258-266.
[14]O’Connor JP,Taneike I,O’Morain C.Improving compliance with helicobacter pylori eradication therapy: when and how?Therap Adv Gastroenterol,2009,2(5):273-279.
[15]Furuta T,Graham DY.Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.Gastroenterol Clin North Am,2010,39(3):465-480.
[16]Hunfeld NG,Touw DJ,Mathot RA,et al.A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.Aliment Pharmacol Ther,2012,35(7):810-818.
[17]Sugimoto M,Shirai N,Nishino M,et al.Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m.,overcoming CYP2C19 genotype.Aliment Pharmacol Ther,2012,36(7):627-634.
[18]Furuta T,Shirai N,Kodaira M,et al.Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.Clin Pharmacol Ther,2007,81(4):521-528.
[19]Sugimoto M,Furuta T.Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.World J Gastroenterol,2014,20(21):6400-6411.
[20]De Francesco V,Margiotta M,Zullo A,et al.Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.Ann Intern Med,2006,144(2):94-100.
[21]Liou JM,Chen CC,Chang CY,et al.Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection:a multicentre clinical trial.J Antimicrob Chemother,2013,68(2):450-456.

备注/Memo

备注/Memo:
*基金项目：“十二五”国家支撑计划课题（2012BAI06B02）；首都卫生发展科研专项（2011-4032-02） **通讯作者，Email：zhouliya123456@163.com ***共同第一作者 ①（北京大学第四临床医学院，北京100096） ②（中国疾病预防控制中心传染病预防控制所，北京102206）
更新日期/Last Update: 2015-06-20